| ||
Aquavit Pharmaceuticals forms Alliance Partnership with Accelrys IT News Online 21, 2012 /PRNewswire/ -- Aquavit Pharmaceuticals, Inc. and Accelrys Software Inc. (NASDAQ: ACCL), a leader in scientific innovation lifecycle management software, have formed an alliance partnership towards the development of Aquavit's PITO-001 and ... See all stories on this topic » | ||
Eutropics Pharmaceuticals signs $1.5M NCI/SBIR contract to develop ... Sacramento Bee CAMBRIDGE, Mass., Sept. 20, 2012 -- /PRNewswire/ -- Eutropics Pharmaceuticals has signed a $1.5M phase 2 contract with the National Cancer Institute Small Business Initiative Research (NCI-SBIR) to commercially develop its proprietary diagnostic assay ... See all stories on this topic » | ||
4 Pharmaceutical Stocks to Sell Now Investorplace.com The ratings of four Pharmaceutical stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell"). Durect (NASDAQ:DRRX) is on the decline this week, earning a D ("sell") after ... See all stories on this topic » | ||
AmerisourceBergen: Pharmaceuticals business has bright future Drug Store News PHILADELPHIA — The pharmaceuticals business will begin picking up in 2014, AmerisourceBergen president and CEO Steve Collis said last week at the wholesaler's ThinkLive Manufacturer's Summit held here. "Next year is a slower brand-to-generic [trend] ... See all stories on this topic » | ||
Study: Physicians give less credence to studies funded by pharmaceutical industry Boston Globe Doctors are less likely to trust studies funded by the pharmaceutical industry even when they are well-designed, a study lead by researchers at Brigham and Women's Hospital and Harvard Medical School found. Recent ethical transgressions in ... See all stories on this topic » | ||
Weighted average formula likely Business Standard The group of ministers (GoM) on the proposed National Pharmaceutical Pricing Policy is likely to recommend the weighted average method to determine prices of essential drugs. The policy, which would bring 348 medicines into its purview, is expected to ... See all stories on this topic » | ||
| ||
Stocks for the Long Run: West Pharmaceutical Services vs. the S&P 500 DailyFinance But there are, of course, companies whose long-term fortunes differ substantially from the index. In this series, we look at how individual stocks have performed against the broad S&P 500. Step on up, West Pharmaceutical Services (NYS: WST) . See all stories on this topic » |
Tip: Use site restrict in your query to search within a site (site:nytimes.com or site:.edu). Learn more.
Delete this alert.
Create another alert.
Manage your alerts.
0 comments:
Post a Comment